Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "John D. Isaacs" Clear advanced filters

  • Here, John Isaacs describes the societal implications of rheumatoid arthritis and how diagnosis and treatment approaches have evolved. He also discusses the future approaches needed for the complete management of this disease.

    • John D. Isaacs
    Comments & Opinion
    Nature Reviews Immunology
    Volume: 10, P: 605-611

  • The use of biologic agents has revolutionized treatment in a number of rheumatic and non-rheumatic autoimmune and inflammatory disorders. In this Review, the authors discuss whether rheumatologists can learn lessons from the application of biologic agents in non-rheumatic diseases such as psoriasis, asthma and multiple sclerosis.

    • Gillian M. Bell
    • Gary Reynolds
    • John D. Isaacs
    Reviews
    Nature Reviews Rheumatology
    Volume: 7, P: 507-516

  • The contributions of key cytokines in rheumatoid arthritis (RA) pathogenesis, including TNF, IL-1, JAK-dependent cytokines, GM-CSF and chemokines, can be considered not only individually, but also in the context of an overall 'RA tissue response'. In this Opinion article, the authors provide an overview of the roles of cytokines in the innate, adaptive and stromal immune responses, and discuss how systematic analysis of cytokine pathways could yield new insights into disease pathogenesis and facilitate stratification for therapy.

    • Iain B. McInnes
    • Christopher D. Buckley
    • John D. Isaacs
    Reviews
    Nature Reviews Rheumatology
    Volume: 12, P: 63-68

  • Clinical use of biologic therapies for rheumatology has revealed that efficacy, toxicity and pharmacodynamic effects can deviate from those predicted. In this review, Issacs and colleagues summarize lessons gleaned from practical experience and discuss how these can inform future development of new biologic therapies.

    • Vibeke Strand
    • Robert Kimberly
    • John D. Isaacs
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 75-92

  • Methotrexate remains the first-line therapy for rheumatoid arthritis (RA). However, not all treated patients respond, and its mechanism of action remains incompletely understood. This Review describes putative mechanisms of action of methotrexate at the low doses used in RA and discusses potential biomarkers of treatment response, which could ultimately inform precision use of this therapy.

    • Philip M. Brown
    • Arthur G. Pratt
    • John D. Isaacs
    Reviews
    Nature Reviews Rheumatology
    Volume: 12, P: 731-742

  • Advances in synovial tissue research have improved our understanding of inflammatory arthritides, particularly rheumatoid arthritis, and have identified potential biomarkers that could be used for diagnosis, disease stratification, and predicting disease course and treatment response.

    • Carl Orr
    • Elsa Vieira-Sousa
    • Douglas J. Veale
    Reviews
    Nature Reviews Rheumatology
    Volume: 13, P: 463-475